OCLS is at $6+ from $2 yesterday, on 4,000,000 shares in the first hour and a half today.
It is a gel that is used to reduce scarring. What is so much better about RXII, that prevents scarring, and a gel that reduces it substantially later?
I am not asking the above rhetorically? The figure of $5,000,000,000 has been used a lot here as the annual sales potential for RXII's sales. NEVER have I seen anything about its competition such as OCLS, its price and whether or not it would be competitive, or its probable need.
My point: Sure RXII seems to #$%$ scarring but what does that really mean in a vacuum where we do not consider alternative palliatives, price of the various alternatives vs. RXII, or need.
How about some discussion on those matters? Do we really have the potential of a triple in one day with RXII, or has OCLS a taken a lot of the potential away?
P.S. I am long RXII but am beginning to think there is less there than meets the eye.
I am personally more excited about the potential of RXI's delivery platform. If that can be patented and licensed to other / larger pharma for pursuit of their own indications, that could be a revenue stream larger than their own therapies. From a cursory read of the ocls news release they do appear to be targeting same type of scarring as RXI. But I don't know anything about the "Vancouver Scale" and how scientific it may or may not be. I do agree in general with the point of your post, i.e., "will they be competing directly with RXI?". I don't know the answer to that.